期刊文献+

帕珠沙星对临床分离致病菌的体外抗菌活性研究 被引量:2

In vitro antibacterial activity of pazufloxacin against clinical isolates
暂未订购
导出
摘要 目的评价帕珠沙星的体外抗菌活性。方法采用琼脂二倍稀释法,测定帕珠沙星与左氧氟沙星对342株临床分离菌株的最低抑菌浓度(MIC)。结果帕珠沙星对革兰阴性菌和革兰阳性菌的MIC90分别为0.06-4和1-16μg/ml。对大肠埃希菌、阴沟肠杆菌、变形菌、铜绿假单胞菌、不动杆菌和链球菌的MIC90为0.06-4μg/ml,是左氧氟沙星的1/2-1/8;对肺炎克雷伯菌、金葡菌和表葡菌与左氧氟沙星抗菌作用相当,MIC90分别为0.5、1、1μg/ml;对流感嗜血杆菌、黏膜炎莫拉菌和粪肠球菌的MIC90为0.5、1、16μg/ml,高于左氧氟沙星(0.25、0.5、8μg/ml)。结论帕珠沙星对革兰阴性菌和革兰阳性菌均具有广谱的抗菌作用,对革兰阴性菌的抗菌活性优于革兰阳性菌。 Objective To evaluate in vitro antibacterial activity of pazufloxacin. Methods The minimum inhibitory concentration (MIC) of pazufloxacin and levofloxacin against 342 clinical isolates was determined by agar dilution method. Result MIC90s of pazufloxacin were 0.06-4μg/ml and 1-16μg/ml respectively against Gram-negative and Gram-positive bacteria. MIC90s of pazufloxacin were 0.06- 4μg/ml against Escherichia coli, Enterobacter cloacae, Proteus spp., Pseudornonas aeruginosa, Acinetobacter spp., and Streptococcus spp. , and those were 1/2-1/8 MIC90s of levofloxacin. MIC90s of pazufloxacin were equal to those of levofloxacin against Klebsiella peurnoniae, Staphylococcus aureus, and S. epiderrnidis. They were 0.5, 1 and 1μg/ml respectively. MIC90s of pazufloxacin (0.5, 1 and 16μg/ml) were higher than those of levofloxacin (0.25, 0.5 and 8μg/ml) agaist Haemophilus influenzae, Moraxella catarrhalis, and Enterococus faecalis. Conclusion Pazufloxacin has a broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria. Antibacterial activity of pazufloxacin against Gram-negative bacteria is superior to Gram-positive bacteria.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2007年第2期117-119,共3页 Chinese Journal of Antibiotics
关键词 帕珠沙星 左氧氟沙星 体外抗菌活性 Pazufloxacin Levofloxacin In vitro antibacterial activity
  • 相关文献

参考文献8

  • 1Nagasawa M, Nakamura S, Miyazaki M, et al. Phototoxieity studies of pazufloxacin mesilate, a novel parenteralquinolone antimicrobial agent-in vitro and in vivo studies[J]. Jpn J Antiboit, 2002,55 (3): 259
  • 2Minami S, Hattori R, Matsuda A. Pharmacological properties and expected clinical role of an injectable newquinolone antibiotic, pazufloxacin mesilate [J]. Nippon Yakurigaku Zasshi,2003,122(2) :161
  • 3Higa F, Akamlne M, Haranaga S, et al. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species[J].J Antimicrob Chemother , 2005, 56 (6) :1053
  • 4Nomura N, Mitsuyama J, Furuta Y, et al. In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone[J].Jpn J Antibiot, 2002,55 (4), 412
  • 5Misuyama J, Miyazaki S, Ishil Y, et al. Antibacterial activity of a new injectable quinolone pazufloxacin mesilate in vitro and in vivo [J]. Jpn J Chemother,1999,47(Suppl 1):1
  • 6Mitsuyama J, Takahata M, Yamashiro Y, et al. Antibacterial activity of a new injectable quinolone, pazufloxacin mesilate, in vitro and in vivo [J]. Jpn J Chemother,1999, 47 (Suppl 1):37
  • 7Takei M, Fukuda H, Kishii R, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition [J]. Antimlcrob Agents Chemother, 2001,45 (12) : 3544
  • 8桂保松,宁宁,孙秀珍,李雅莉,崔社环,靳凤乐,韩雪芳,王养维.帕珠沙星注射液治疗急性细菌性感染104例的多中心随机对照试验[J].中国新药与临床杂志,2005,24(7):532-535. 被引量:16

二级参考文献5

  • 1TAKAHASHI H, HAYAKAWA I, AKIMOTO T. The history of the development and changes of quinolone antibacterial agents [J].Yakushigaku Zasshi, 2003,38 (2): 161-179.
  • 2MINAMI S, HATTORI R, MATSUDA A. Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate [J]. Nippon Yakurigaku Zasshi, 2003,122(2) :161-178.
  • 3NOMURA N, MITSUYAMA J, FURUTA Y, et al. In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone [J]. Jpn J Antibiot ,2002,55 (4) :412-439.
  • 4NAGASAWA M, NAKAMURA S, MIYAZAKI M, et al. Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent-in vitro and in vivo studies[J]. Jpn J Antibiot,2002, 55 (3) :259-269.
  • 5RUBINSTEIN E. History of quinolones and their side effects [J].Chemotherapy,2001,47 Suppl 3:3-8.

共引文献15

同被引文献18

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部